2026-09-24 → 09-26 Capital Bear
Tempus AI CEO Lefkofsky Sells 250K Shares for ~$19.37M CEO sold at avg $77.47 on Sep 22, extending recent insider selling trend
D1 +7.4% · +5d -7.0%
› 2 waves of this story2026-09-24 Insider sale of ~10% stake may draw attention to internal confidence2026-09-26 CEO sold at avg $77.47 on Sep 22, extending recent insider selling trend2026-09-22 Insider selling
Insider selling $19.4M (1) D1 -1.1% · +5d +7.0%
2026-09-22 Analyst Bull
Tempus AI Draws Bullish Analyst Notes on Data, MRD Growth Multiple analysts reiterate Buy on oncology volumes and data licensing
D1 -1.1% · +5d +7.0%
2026-09-21 Company Bull
Tempus AI Extends Recursion Data Partnership to 2029, Licenses RNA Model Committed payments replace discretionary fees, boosting data and AI capabilities
D1 +0.2% · +5d +9.0%
2026-09-20 Capital Bear
Tempus AI Executives Sell Shares Multiple executives sold shares in mid-to-late September, involving significant amounts.
D1 +0.2% · +5d +9.0%
2026-09-17 Insider selling
Insider selling $16.9M (3) D1 +14.8% · +5d +2.3%
2026-09-01 → 09-11 Analyst Bull
H.C. Wainwright Maintains Buy, Raises PT to $66 Analyst cites positive trial read-through improving strategic value and supporting higher volumes
D1 -1.2% · +5d -1.6%
› 2 waves of this story2026-09-01 Analyst cites three increasingly visible growth drivers: Personalis acquisition, INTerpath-001, and xT CDx approval2026-09-11 Analyst cites positive trial read-through improving strategic value and supporting higher volumes2026-09-11 Company Bull
Tempus Launches 100,000-Genome Multimodal Dataset Initiative Company announcement and multiple X posts confirm long-term 1M genome target, strengthening AI healthcare data leadership
D1 +0.5% · +5d +31.9%
2026-09-10 Company Bull
Tempus Secures Up to $9.5M ARPA-H Award for Autonomous AI in Cardiology Company announcement confirms selection for ARPA-H ADVOCATE program, funding deployment of autonomous AI in cardiology.
D1 -4.1% · +5d +36.8%
2026-09-02 → 09-04 Analyst Bull
Multiple Analysts Favor TEM Ahead of Conference Appearance WSJ sees potential slice of MRNA/MRK personalized cancer therapy
D1 -0.5% · +5d -5.2%
› 2 waves of this story2026-09-02 Analyst sees D&A mispriced vs peers, with five under-appreciated growth levers2026-09-04 WSJ sees potential slice of MRNA/MRK personalized cancer therapy2026-09-04 Company
Tempus AI to Participate in Morgan Stanley Global Healthcare Conference CEO Eric Lefkofsky to join fireside chat
D1 -0.1% · +5d -3.7%
2026-08-22 → 09-02 Company Bear
Tempus AI Director Nadja West Sells 3,000 Shares for $207,000 Director sale continues recent insider selling trend, though small in size
D1 -9.0% · +5d -4.7%
› 2 waves of this story2026-08-22 CEO, legal, accounting, and data chiefs sold shares for tax withholding, totaling millions2026-09-02 Director sale continues recent insider selling trend, though small in size2026-09-01 Analyst
Piper Sandler upgrades to Overweight D1 -1.2% · +5d -1.6%
2026-08-25 Insider selling
Insider selling $17.1M (1) D1 +3.9% · +5d -9.4%
2026-08-24 Product Bull
Tempus AI Receives FDA Clearance for ECG-PH, Third Cardiovascular AI Device FDA 510(k) clearance expands AI diagnostic portfolio, strengthening cardiovascular footprint
D1 -9.0% · +5d -4.7%
2026-08-22 Analyst Bull
BTIG Raises Tempus AI Price Target to $80 Analyst raises PT, maintains buy, stock up 8.3% intraday
D1 -9.0% · +5d -4.7%
2026-08-20 Capital
Bank of America Cuts Tempus AI Stake by 63.6% Institutional holding change reflects capital movement
D1 +8.8% · +5d +6.1%
2026-08-19 → 08-20 Product Bull
Moderna Breakthrough Lifts Personalized Medicine Ecosystem, Benefiting Tempus Across Sequencing, Data, Diagnostics MRNA surge drives sector rerating; Tempus spans sequencing, data, diagnostics
D1 +24.1% · +5d +11.8%
› 2 waves of this story2026-08-19 First large-scale validation of personalized cancer vaccines expands market for tumor sequencing and MRD monitoring2026-08-20 MRNA surge drives sector rerating; Tempus spans sequencing, data, diagnostics2026-08-18 Insider selling
Insider selling $11.6M (6) D1 -4.4% · +5d +39.2%
2026-08-18 Earnings Bull
Tempus AI Reports First GAAP Profit, Raises 2026 Revenue Guidance Data business accelerates, operating leverage shows; guidance raised to $1.595B-$1.605B
D1 -4.4% · +5d +39.2%
2026-08-18 Company Bull
Tempus Signs Exclusive Distribution Agreement with TempraMed in Panama Converts prior LOI to definitive deal; first bulk order delivered to clinics and pharmacies
D1 -4.4% · +5d +39.2%
2026-07-31 Earnings Bull
Tempus AI Q2 Revenue Beats, Raises FY Guidance Q2 loss narrows, revenue beats, FY26 sales guidance raised to $1.595-1.605B; stock initially up 6.6% then reset lower.
D1 -0.9% · +5d +18.6%
› 2 waves of this story2026-07-31 Q2 revenue of $382.5M beat estimates, adjusted EPS loss narrowed, and FY26 revenue guidance raised.2026-07-31 Q2 loss narrows, revenue beats, FY26 sales guidance raised to $1.595-1.605B; stock initially up 6.6% then reset lower.2026-07-31 Capital
CEO Sells 250K Shares; Needham Maintains Buy Founder-CEO reduces indirect stake ~4% via pre-scheduled plan, retains ~6.5M shares; Needham reiterates Buy, PT $75.
D1 -0.9% · +5d +18.6%
2026-07-30 8-K filing
8-K: Item 2.02, Item 7.01, Item 9.01 D1 +6.6% · +5d +4.1%
2026-07-30 Earnings
Earnings report D1 +6.6% · +5d +4.1%
2026-07-28 Insider selling Bear
Insider selling $10.5M (1) D1 +0.0% · +5d +9.7%
2026-07-20 → 07-24 Capital Bull
Tempus AI to Acquire Personalis for $1.5B in Stock Deal H.C. Wainwright reiterates Buy, sees deal expanding capabilities in $20B MRD market
D1 -7.7% · +5d -11.4%
› 4 waves of this story2026-07-20 Expands reach in cancer testing market; all-stock transaction2026-07-20 Deal terms confirmed at $16.25/share, 6% premium, adding MRD platform for cancer recurrence monitoring2026-07-22 Executives cite $20B+ MRD market, deal aims to expand oncology diagnostics and biopharma data2026-07-24 H.C. Wainwright reiterates Buy, sees deal expanding capabilities in $20B MRD market2026-07-22 Product Bull
Tempus AI Launches OneOme Pharmacogenomics Testing Nationwide Following 2025 acquisition, platform analyzes drug-gene interactions with results in under 5 days, advancing precision medicine.
D1 -4.1% · +5d -11.5%
